Congenital portosystemic venous shunt

por Papamichail, M., Pizanias, M., Heaton, N.
Publicado 2017

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo

por Gritzapis, A D, Perez, S A, Baxevanis, C N, Papamichail, M
Publicado 2005

Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.

por Baxevanis, C. N., Dedoussis, G. V., Gritzapis, A. D., Stathopoulos, G. P., Papamichail, M.
Publicado 1994

Induction of anti-tumour lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytes.

por Baxevanis, C. N., Tsiatas, M. L., Cacoullos, N. T., Spanakos, G., Liacos, C., Missitzis, I., Papadhimitriou, S. I., Papamichail, M.
Publicado 1997

Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells

por Gritzapis, A D, Mamalaki, A, Kretsovali, A, Papamatheakis, J, Belimezi, M, Perez, S A, Baxevanis, C N, Papamichail, M
Publicado 2003

Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours

por Sotiropoulou, P A, Perez, S A, Iliopoulou, E G, Missitzis, I, Voelter, V, Echner, H, Baxevanis, C N, Papamichail, M
Publicado 2003

Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope

por Sotiriadou, R, Perez, S A, Gritzapis, A D, Sotiropoulou, P A, Echner, H, Heinzel, S, Mamalaki, A, Pawelec, G, Voelter, W, Baxevanis, C N, Papamichail, M
Publicado 2001